Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth and its business partner, Nycomed, have launched a generic version of Protonix tablets in the US, in response to the at-risk launch of generic pantoprazole tablets in the US by Teva Pharmaceuticals US.
Subscribe to our email newsletter
Teva launched generic Protonix on December 21, 2007. Wyeth’s own generic version of Protonix, a gastrointestinal drug, will be distributed by Prasco.
Bernard Poussot, president and CEO of Wyeth, said: “We believe the Protonix compound patent is strong and we will vigorously pursue our litigation against Teva and other infringing generics. Going forward, we will continue to seek an injunction against any infringement of this patent, as well as monetary damage, including lost profits, from Teva.”